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SUMMARY
INTRODUCTION: The association between the between IL-10 -1082A>G (rs1800896) polymorphism and breast cancer has been evalu-
ated by several number case-control studies. However, these studies might be underpowered to reveal the true association.
OBJECTIVE: We have performed a comprehensive meta-analysis to investigate the association IL-10 -1082A>G polymorphism and 
breast cancer.
MATERIALS AND METHODS: A systematic literature search was conducted using PubMed, Google Scholar, and Web of Science up to 
September 20, 2017. Data was analysed with CMA software to identify the strength of the association by pooled odds ratios (ORs) with 
corresponding 95% confidence intervals (CIs).
RESULTS: A total of 17 case-control studies involving 3275 cases and 3416 controls obtained from database searches were examined. 
Overall, there was no significant association between IL-10 -1082A>G polymorphism and breast cancer risk under all genetic models. 
No significant publication bias was found for the five genetic models (G vs. A: OR = 1.184, 95% CI = 0.895-1.180, p= 0.230; GG vs. AA: 
OR = 1.430, 95% CI = 0.927-2.204, p= 0.106; GA vs. AA: OR = 0.966, 95% CI = 0.765-1.221, p= 0.774; GG+GA vs. AA: OR = 0.957, 95% CI 
= 0.697-1.314, p= 0.786; and GG vs. GA+AA: OR = 1.221, 95% CI = 0.981-1.518, p= 0.073). Moreover, there was no significant association 
between the IL-10 -1082A>G polymorphism and breast cancer risk by ethnicity.
CONCLUSION: Our findings indicated that IL-10 -1082A>G (rs1800896) polymorphism might not be a risk factor for the development 
of breast cancer.
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INTRODUCTION
Breast cancer is one of the most commonly diag-
nosed invasive malignancies.1-3 Breast cancer is the 
second most common cancer-related death in wom-
en worldwide and accounts for 15.4% of cancer-relat-
ed deaths in women.4,5 The pathogenesis of breast 
cancer is multifactorial. Hereditary breast cancer 
accounts for only 5-10% of all breast cancer cases 
and germline mutations with the two major breast 
cancer susceptibility genes BRCA1 and BRCA2, being 
responsible approximately for 2-3% of all cases.6,7 Be-
sides gene tests to identification of high-risk BRCA1 
or BRCA2 mutations carriers, the ability to predict 
breast cancer development, is not well established 
yet.7,8 The findings suggest that accumulation of sev-
eral polymorphic variants is responsible for elevated 
risk of breast cancer.9,10 However, the association of 
genetic variations with the clinical characteristics 
and prognosis in breast cancer has not been fully 
identified.11
The human interleukin 10 gene is a steroid hor-
mone receptor gene located on chromosome 6 at 
6q25.1. It contains eight exons spanning 295 kb.12,13 
The IL-10 promoter is highly polymorphic and three 
most common SNPs, including -1082, -819, and -592, 
within this region have been correlated with IL-10 
production.14 Several epidemiological studies have 
evaluated IL-10 -1082 polymorphism and its asso-
ciation with breast cancer.15-21 However, the effects 
of polymorphisms in rs2077647, rs2228480 and 
rs3798577 were also controversial. It is clear that the 
number of studies, time of analysis and new studies 
included in a meta-analysis directly influences the 
credibility and stability of the findings. Therefore, 
we have performed this systematic review and me-
ta-analysis to more accurately assess the association 
between IL-10 -1082A>G (rs1800896) polymorphism 
and breast cancer risk, using more recent published 
studies.
MATERIALS AND METHODS
Search Strategies
A computerized literature search of different data-
bases, including PubMed, Web of Science, EMBASE, 
China National Knowledge Infrastructure (CNKI), 
China Biology Medicine (CBM) and Google Schol-
ar was conducted up to September 20, 2017. The 
search strategy identified all possible studies using 
combinations of the following terms and keywords: 
‘’Breast cancer’’, ‘’interleukin 10’’, ‘’IL-10 gene’’, ‘’-
1082A>G’’, ‘’rs1800896’’, ‘’polymorphism’’, ‘‘variant’’ 
and ‘‘mutation’’. Furthermore, we have manually 
screened the bibliographies of relevant articles and 
reviews for additional studies that were not captured 
by the database search. Publications in both English 
and Chinese languages were included, and only pub-
lished studies with full-text articles were included.
Inclusion and Exclusion Criteria
The studies included in this meta-analysis had to 
meet the following criteria: (1) any study published as 
a case-control or cohort study that evaluated the as-
sociation between IL-10 -1082A>G (rs1800896) poly-
morphism and breast cancer risk; (2) the numbers of 
cases and controls for each genotype were reported 
or sufficient data was provided to calculate the odds 
ratio (OR). The following were exclusion criteria: (1) 
not designed as case-control or cohort studies, (2) re-
views, abstracts or animal studies; (3) studies were 
not relevant to IL-10 -1082A>G (rs1800896) poly-
morphism and breast cancer; (4) not providing the 
genotype frequencies; and (5) duplicate of previous 
publication. If multiple studies from the same case 
series were available, the one including the most in-
dividuals was used in the analysis.
Data Extraction
The information was carefully extracted from all 
of the eligible studies independently by two inves-
tigators based on the inclusion criteria listed above 
and then examined by an expert in headaches. From 
each of the included articles the following data were 
collected: first author, year of publication, country of 
origin, ethnicity, total number of cases and controls, 
frequencies of genotypes, genotyping technique, 
minor allele frequencies (MAFs), P-value for Hardy–
Weinberg equilibrium (HWE). In case of disagree-
ment, consensus was obtained on every item by joint 
review of the study. The different ethnic descents 
were categorized as Asian, European, American or 
African.
Statistical Methods
The odds ratio (OR) and its 95% confidence inter-
val (CI) was used to assess the strength of association 
between IL-10 -1082A>G (rs1800896) polymorphism 
and breast cancer risk under allele model (G vs. A), 
homozygote model (GG vs. AA), heterozygote model 
(GA vs. AA), dominant model (GG+GA vs. AA), and 
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recessive model (GG vs. GA+AA). The significance of 
the pooled OR was determined by the Z-test. Hetero-
geneity assumption was checked by the Chi-square-
based Q-test.22 The effect of heterogeneity was quan-
tified using the I2 value as well as P value. A P-value 
less than 0.10 for the Q-test and I2 value >50% indi-
cates existence of heterogeneity among studies. The 
pooled OR was assessed in both fixed-effects model 
(the Mantel–Haenszel method)23 and random-effects 
model (the DerSimonian and Laird methods),24 so 
the pooled OR estimates of the included studies was 
calculated by the random-effects model. Otherwise, 
the fixed-effects model was used. Sensitivity analy-
ses were performed to evaluate the stability of the 
results, namely, a single study in the meta-analysis 
was omitted in each turn to reflect the influence of 
the single data set on the pooled results. Deviation 
from the Hardy–Weinberg equilibrium (HWE) was 
checked among controls through exact test. Sub-
group analyses by ethnicity and studies quality were 
performed subsequently. Begg’s funnel plot was car-
ried out to examine the potential publication bias be-
tween studies (P value less than 0.10 was selected to 
be statistically significant).25 In addition, Egger’s test 
on the natural logarithm scale of the OR was used to 
estimate the funnel plots asymmetry. 26 All statisti-
cal analyses were performed using Comprehensive 
Meta-Analysis (CMA) software version 2.0 (Biostat, 
USA). All P values were two-sided, and P<0.05 was 
considered statistically significant.
RESULTS
Characteristics of Selected Studies
We have identified 211 published case-control 
studies before September 20, 2017 in the database 
search and by manual screening. Of these studies, 
the first screening excluded 109 publications that 
were excluded as duplicates or not relevant, leav-
ing 102 studies for further selection. After removal 
of review articles, case reports, and those that did 
not meet our inclusion criteria, a total of 17 articles 
4,12,13,15-21,27-33 with 3,275 cases and 3,416 controls were 
finally included in our meta-analysis. A flow diagram 
schematizing the inclusion and exclusion process of 
identified articles with the inclusion criteria is pre-
FIGURE 1. FLOW CHART OF LITERATURE SEARCH AND STUDY SELECTION.
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sented in Figure 1. These studies were published be-
tween 2003 and 2017 and the average sample size 
was 192 cases per study. Of the 17 case-control studies 
focusing on the relationship between IL-10 -1082A>G 
(rs1800896) polymorphism and breast cancer, sev-
en were conducted among Caucasians,15-17,18-21 with 
1336 cases and 1388 controls, eight among Asians4,12, 
27-29,31,32 with 1,754 cases and 1,898 controls, and two 
among Africans,30,33 with 185 cases and 130 controls. 
The studies were carried out in Italy, UK, USA, Cana-
da, Turkey, Iran, China, India, Jordan and Egypt. The 
detailed characteristics of the included studies were 
shown in Table 1. The distribution of the genotypes in 
the control group of five case-control studies13,27,30-32 
was not in agreement with Hardy-Weinberg equilib-
rium (HWE). Twelve of 17 studies were in accordance 
with HWE were defined as high-quality studies. The 
genotypes distributions in the individual studies 
were presented in Table 1.
Quantitative synthesis
The main characteristics of these studies were 
listed in Table 2. The heterogeneity between studies 
was significant under all genetic models. Therefore, 
the random effect model was used for calculating the 
pooled OR. Overall, there was no significant associ-
TABLE 1. MAIN CHARACTERISTICS OF STUDIES INCLUDED IN THIS META-ANALYSIS. 
First  
Author/
Year
Country 
Ethnicity
Case Con-
trol
Cases Controls MAFs HWE
Genotype Allele Genotype Allele
AA AG GG A G AA AG GG A G
Giordani 
2003 15
Italy (Cau-
casian)
125 100 60 54 11 174 76 33 51 16 117 83 0.415 0.614
Smith 2004 
16
UK (Cau-
casian)
144 263 32 58 39 136 122 46 120 57 250 276 0.524 0.238
Guzowski 
2005 17
USA (Cau-
casian)
50 25 10 28 12 48 52 9 12 4 30 20 0.400 1.000
Abdolra-
him-Zadeh 
2005 27
Iran 
(Asian)
275 320 119 116 40 177 373 146 125 49 417 223 0.348 0.012
Balasu-
bramanian 
2006 18
UK (Cau-
casian)
497 498 121 253 123 499 495 117 260 121 494 502 0.504 0.323
Onay 2006 
19
Canada 
(Cauca-
sian)
398 372 90 205 103 385 411 107 194 71 408 336 0.451 0.307
Scola 2006 
20
Italy (Cau-
casian)
84 106 28 40 16 96 72 40 45 21 125 87 0.410 0.206
Gonullu 
2007 21
Turkey 
(Cauca-
sian)
38 24 13 22 3 48 28 16 7 1 39 9 0.187 0.834
Kong 2010 
4
China 
(Asian)
315 322 285 29 1 599 31 285 35 2 605 39 0.060 0.422
Pooja 2012 
12
India 
(Asian)
200 200 132 60 8 324 76 145 50 5 340 60 0.150 0.781
Liang 2013 
28
China 
(Asian)
40 89 31 9 0 71 9 73 16 0 162 16 0.089 0.351
Vinod 2015 
29
India 
(Asian)
125 160 76 31 18 183 67 67 78 15 212 108 0.337 0.254
Alsuhaibani 
2016 30
Egypt 
(African)
80 80 16 47 17 79 81 14 50 16 78 82 0.512 0.024
Atoum 
2016 31
Jordan 
(Asian)
202 210 157 29 16 343 61 151 42 17 344 76 0.181 0.001
Tian 2017 
13
China 
(Asian)
312 312 51 132 129 234 390 27 154 131 208 416 0.666 0.050
Maruthi 
2017 32
India 
(Asian)
285 285 80 146 59 262 308 89 159 37 234 336 0.408 0.009
Sabet 2017 
33
Egypt 
(African)
105 50 15 41 49 71 139 27 21 2 75 25 0.250 0.396
MAFs: minor allele frequencies; HWE: Hardy–Weinberg equilibrium
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FIGURE 2. FOREST PLOT OF IL-10 -1082A>G POLYMORPHISM AND BREAST CANCER RISK. A: OVERALL 
(RECESSIVE MODEL: GG VS. GA+AA); B: ASIANS (DOMINANT MODEL: GG+GA VS. AA), C: HWE STATUS (ALLELE 
MODEL: G VS. A).
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ation between the IL-10 -1082A>G (rs1800896) poly-
morphism and breast cancer risk under the allele 
model (G vs. A: OR = 1.184, 95% CI = 0.895-1.180, p= 
0.230), homozygote model (GG vs. AA: OR = 1.430, 
95% CI = 0.927-2.204, p= 0.106), heterozygote mod-
el (GA vs. AA: OR = 0.966, 95% CI = 0.765-1.221, p= 
0.774), dominant model (GG+GA vs. AA: OR = 0.957, 
95% CI = 0.697-1.314, p= 0.786), and recessive model 
(GG vs. GA+AA: OR = 1.221, 95% CI = 0.981-1.518, p= 
0.073, Figure 2A).
We have also carried out subgroup analyses that 
were stratified by ethnicity. Overall, no obvious ev-
idence of associations between the IL-10 -1082A>G 
(rs1800896) polymorphism and susceptibility to the 
breast cancer were found in Caucasian, Asian and Af-
rican populations under all genetic models (Figure 2B). 
Moreover, subgroup analysis of studies with high quali-
ty (HWE status) did not show significant association be-
tween IL-10 -1082A>G (rs1800896) polymorphism and 
increased risk of breast cancer (Figure 2C). The results 
of these analyses are shown in Table 2 and Figure 2.
Sensitivity Analysis
Sensitivity analysis was performed to confirm 
the stability and liability of the meta-analysis by 
sequentially omitting individual eligible studies. 
When any single study was excluded, the corre-
sponding ORs were not materially changed (data 
was not shown), indicating the stability of our re-
sults. Additionally, we excluded the studies that 
genotype distribution in the controls deviating from 
HWE, and the corresponding pooled ORs were not 
significantly changed.
Publication Bias
Table 2 and Figure 3 present information related 
to the publication bias. We have performed Funnel 
plot and Egger’s linear regression to assess the pub-
lication bias of the included studies. The shapes of 
the funnel plots did not reveal any evidence of obvi-
ous asymmetry (Figure 3). In addition, the results of 
Begg’s test also showed that there was no strong sta-
tistical evidence of publication bias.
FIGURE 3. BEGG’S FUNNEL 
PLOTS (PUBLICATION BIAS) 
FOR THE ASSOCIATION 
BETWEEN IL-10 -1082A>G 
POLYMORPHISM AND RISK 
OF BREAST CANCER. A: 
ALLELE MODEL (G VS. A); B: 
RECESSIVE MODEL (GG VS. 
GA+AA).
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TABLE 2. RESULTS OF META-ANALYSIS FOR RS1800896 (-1082A>G) POLYMORPHISM AND RISK OF BREAST CANCER.
Sub-
group
Genetic model Type of 
model
Heterogeneity Odds ratio Publication Bias
I2% PH OR 95% CI Ztest POR PBeggs PEggers
Overall G vs. A Random 91.84 ≤0.001 1.184 0.895-1.180 1.180 0.230 0.149 0.722
GG vs. AA Random 80.82 ≤0.001 1.430 0.927-2.204 1.617 0.106 0.843 0.656
GA vs. AA Random 69.43 ≤0.001 0.966 0.765-1.221 -0.287 0.774 0.964 0.936
GG+GA vs. AA Random 84.38 ≤0.001 0.957 0.697-1.314 -0.271 0.786 0.685 0.690
GG vs. GA+AA Fixed 49.63 0.013 1.221 0.981-1.518 1.792 0.073 0.921 0.990
By Ethnicity
Caucasian
G vs. A Random 77.38 ≤0.001 1.018 0.781-1.327 0.135 0.893 0.367 0.796
GG vs. AA Random 83.43 ≤0.001 1.574 0.779-3.183 1.264 0.206 1.000 0.715
GA vs. AA Random 59.18 0.023 1.067 0.769-1.481 0.391 0.696 0.548 0.413
GG+GA vs. AA Random 88.89 ≤0.001 0.876 0.458-1.675 -0.400 0.689 0.367 0.935
GG vs. GA+AA Fixed 22.75 0.256 1.159 0.963-1.394 1.561 0.118 0.763 0.854
Asian
G vs. A Random 94.51 ≤0.001 1.100 0.670-1.805 0.377 0.706 0.173 0.683
GG vs. AA Fixed 50.38 0.060 1.005 0.784-1.286 0.036 0.972 1.000 0.985
GA vs. AA Random 72.47 0.001 0.803 0.578-1.116 -1.308 0.191 0.107 0.408
GG+GA vs. AA Random 68.18 0.003 0.857 0.643-1.143 -1.050 0.294 0.536 0.489
GG vs. GA+AA Fixed 14.56 0.319 1.146 0.937-1.403 1.326 0.185 0.763 0.774
African
G vs. A Random 96.13 ≤0.001 2.377 0.409-13.808 0.965 0.355 NA NA
GG vs. AA Random 94.09 ≤0.001 6.104 0.139-267.71 0.938 0.348 NA NA
GA vs. AA Random 83.36 0.014 1.700 0.410-7.055 0.731 0.465 NA NA
GG+GA vs. AA Random 92.78 ≤0.001 2.448 0.308-19.481 0.846 0.397 NA NA
GG vs. GA+AA Random 91.91 ≤0.001 4.446 0.243-81.259 1.006 0.314 NA NA
High Quality Studies
G vs. A Random 85.14 ≤0.001 1.170 0.887-1.542 1.112 0.266 0.303 0.397
GG vs. AA Random 82.01 ≤0.001 1.842 0.991-3.423 1.932 0.053 0.436 0.952
GA vs. AA Random 73.26 ≤0.001 1.076 0.785-1.474 0.455 0.649 0.537 0.335
GG+GA vs. AA Random 88.06 ≤0.001 1.036 0.649-1.654 0.150 0.881 0.303 0.648
GG vs. GA+AA Random 58.11 0.008 1.330 0.948-1.866 1.648 0.099 0.876 0.433
NA; not applicable.
Minor Allele Frequency
The present data revealed variation in the minor 
allele frequency of the IL-10 -1082A>G polymorphism 
worldwide (Table 1). The minor allele frequency range 
was from 18.7% (Turkey) to 52.4% (UK) among Cauca-
sians, 6% (China) to 66.6% (China) among Asians, 25% 
to 51.2% among Africans (Egypt).
Discussion
Previous meta-analysis by Dai et al.34, demon-
strated that IL-10 -1082A>G polymorphism did not 
significantly associate with breast cancer risk. They 
have included only nine case-control studies with 
1851 cases and 1910 controls on IL-10 -1082A>G 
polymorphism association. To further explore and 
examine the association of IL-10 -1082A>G poly-
morphism with breast cancer, we conducted this 
meta-analysis only with most recently published 
studies on different populations. Compared with 
the previous meta-analyses,14 in this meta-analysis 
we have focused only on association between -10 
-1082A>G polymorphism and breast cancer using 
17 case-controls studies with 3275 cases and 3416 
controls. However, Dai et al.34 study essentially re-
main an open field, as meta-analysis of their results’ 
reliability and the number of studies were consid-
erably smaller than that needed to reach robust 
conclusions. Moreover, they have not included the 
Abdolrahim-Zadeh et al.27 study that was published 
in 2005 in Iran. Also, in the current meta-analysis, 
we have carried out subgroup analysis by ethnicity 
among African population. Overall, our results were 
consistent with Dai et al.34 results and did not show 
a significant relationship between IL-10 -1082A>G 
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polymorphism and breast cancer. In the subgroup 
analysis by ethnicity, there was also no association 
between IL-10 -1082A>G polymorphism and breast 
cancer risk in Caucasians, Asians and Africans.
Between-study heterogeneity is a common prob-
lem in meta-analysis for genetic association studies. 
35,36 In the current meta-analysis, there was a signif-
icant heterogeneity in association of IL-10 -1082A>G 
(rs1800896) polymorphism under all genetic models. 
A number of characteristics that vary among studies 
could be the sources of heterogeneity such as age, gen-
der, ethnicity, sample size, including criteria, source 
of controls, and genotyping method.35,37 Therefore, 
we used meta-regression by ethnicity, which aim to 
reduce heterogeneity; however, we did not find any 
meaningful reduction in stratified analysis by ethnic 
and high quality studies, both of which were consid-
ered to be the relevant factors of Heterogeneity.
The main strengths of the current meta-analysis 
were obtaining more precise estimates, absence of 
publication bias, pooled data from studies from dif-
ferent ethnicities and sensitivity analysis indicated 
that our results were statistically robust. Despite 
these advantages, our meta-analysis also has some 
limitations which should be acknowledged when 
interpreting the results. First, the sample size was 
relatively small, and all data were from case-con-
trol studies. Second, we have included only studies 
that were published in English and Chinese lan-
guages and available full-text papers in the current 
meta-analysis; therefor, some eligible studies that 
have not been unpublished or were reported in other 
languages were missed, which may bias the power 
of our results. Third, the current meta-analysis re-
sults were based on single-factor estimates without 
adjustment for other risk factors such as age, gen-
der, folate status, and specific environmental or life-
style factors, should be conducted if possible. Finally, 
gene-gene, gene-environment or even the different 
polymorphisms of the IL-10 gene interactions were 
not estimated in this meta-analysis due lacking of the 
sufficient data.
In conclusion, our meta-analysis suggests that 
IL-10 -1082A>G (rs1800896) polymorphism not asso-
ciated with an increased risk of breast cancer. Never-
theless, more studies are warranted to confirm the 
results and to establish the underlying molecular 
mechanisms that are involved.
RESUMO
INTRODUÇÃO: A associação entre o polimorfismo IL-10 -1082A> L (rs1800896) e o câncer da mama foi avaliada por vários estudos de 
casos-controle. No entanto, esses estudos podem ser insuficientes para revelar a verdadeira associação.
OBJETIVO: Efetuamos uma meta-análise abrangente para investigar a associação entre o polimorfismo IL-10 -1082A> G e câncer de 
mama.
MATERIAIS E MÉTODOS: Uma busca sistemática da literatura foi conduzida usando PubMed, Google Scholar e Web of Science até 20 de 
setembro de 2017. Os dados foram analisados com o software CMA para identificar a força da associação por proporções compartil-
hadas (RUP) com correspondentes intervalos de confiança de 95% (ICs).
RESULTADOS: Um total de 17 estudos de casos-controle envolvendo 3.275 casos e 3.416 controles obtidos a partir de pesquisas de banco 
de dados foram examinados. Em geral, não existe uma associação significativa entre o polimorfismo IL-10 -1082A> G e o risco de 
câncer de mama, sob todos os modelos genéticos. Não foi encontrado nenhum viés de publicação significativo para os cinco modelos 
genéticos (G vs. A: OR = 1,184, IC 95% = 0,895-1,180, p=0,230; GG vs. AA: OR = 1,430, IC 95% = 0,927-2,204, p=0,106; GA vs. AA: OR 
= 0,966, IC 95% = 0,765-1,221, p=0,774; GG + GA vs. AA: OR = 0,957, IC 95% = 0,697-1,314, p=0,786 e GG vs. GA + AA: OR = 1,221, IC 
95% = 0,981-1,518, p=0,073). Além disso, não houve associação significativa entre o polimorfismo IL-10 -1082A> L e o risco de câncer 
de mama por etnia.
CONCLUSÃO: Nossos resultados indicam que o polimorfismo IL-10 -1082A> G (rs1800896) não pode ser um fator de risco para o desen-
volvimento de câncer de mama.
PALAVRAS-CHAVE: Neoplasias da mama. Interleucina-10. Polimorfismo genético. Metanálise.
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